Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSINGLE-DOSEStandard

EMRELIS

TELISOTUZUMAB VEDOTIN-TLLV

Standard Dose
100MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview EMRELIS is listed in Drugs@FDA under application 761384 (BLA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient TELISOTUZUMAB VEDOTIN-TLLV Form and strength VIAL;SINGLE-DOSE - 100MG Sponsor ABBVIE INC Submission history Latest submission status date: 2025-05-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview EMRELIS is listed in Drugs@FDA under application 761384 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient TELISOTUZUMAB VEDOTIN-TLLV Form and strength VIAL;SINGLE-DOSE - 100MG Sponsor ABBVIE INC Submission history Latest submission status date: 2025-05-14 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.